STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study

NCT00526396 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: cisplatin
DRUG: etoposide
DRUG: cisplatin
DRUG: etoposide

Sponsor

National Cancer Institute, Naples